BANK VONTOBEL/CALL/ROCHE GS/310/0.1/21.06.24 Stock

Warrant

DE000VV51K53

Delayed Deutsche Boerse AG 11:01:15 2024-05-17 am EDT
0.001 EUR 0.00% Intraday chart for BANK VONTOBEL/CALL/ROCHE GS/310/0.1/21.06.24
6 months-98.48%
Current year-98.55%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-17 0.001 0.00%
24-05-16 0.001 0.00%
24-05-15 0.001 0.00%
24-05-14 0.001 0.00%
24-05-13 0.001 0.00%

Delayed Quote Deutsche Boerse AG

Last update May 17, 2024 at 11:01 am EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VV51K5
ISINDE000VV51K53
Date issued 2022-08-02
Strike 310 CHF
Maturity 2024-06-21 (35 Days)
Parity 10 : 1
Emission price 3.15
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 4.87
Lowest since issue 0.001
Delta0.01x
Omega 25.54
Premium30.8x
Gearing1921.46x
Moneyness 0.7648
Difference Strike 72.9 CHF
Difference Strike %+23.52%
Spread 0.023
Spread %95.83%
Intrinsic value 0.000000

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
234.8 CHF
Average target price
279.4 CHF
Spread / Average Target
+18.99%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW